Medication info
Dapagliflozin Metformin Sustained Release Tablet 5/500 mg

Dapagliflozin Metformin Sustained Release Tablet 5/500 mg

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›Strength being verifiedDapagliflozin Propanediol Hydrate›Strength being verified
Manufacturer / importer
Dong-A ST Co., Ltd.
Appearance
Orange to dark orange rectangular film-coated double-layer tablet consisting of immediate-release layer and sustained-release layer
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202300351 · Approved 2023.01.27 · Insurance code 642507690

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two tablets of 5mg/1000mg. For patients who have not previously received pharmacological treatment for diabetes and whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients who have not previously received pharmacological treatment for diabetes, the recommended starting dose of this medicine is one tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions to metformin. For patients being treated with metformin, the recommended dose of dapagliflozin is 10mg once daily. The dose of this medicine should provide the patient's current metformin dose or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. For patients switching to this medicine from combination therapy with dapagliflozin and metformin, treatment with this medicine may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to decline in elderly patients, this medicine should be used with caution as age increases.

Ingredients

Manufacturer
Dong-A ST Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • blood sugar control disorder
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is used alongside dietary and exercise therapy to improve blood sugar control in adult patients with type 2 diabetes. It increases effectiveness by using dapagliflozin and metformin in combination, especially in patients whose blood sugar is not adequately controlled. It can also be used in patients with cardiovascular disease or risk factors for cardiovascular disease, in which case caution is advised according to professional guidelines. This medication may improve blood sugar control and help manage cardiovascular health.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two tablets of 5mg/1000mg. For patients who have not previously received pharmacological treatment for diabetes and whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients who have not previously received pharmacological treatment for diabetes, the recommended starting dose of this medicine is one tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions to metformin. For patients being treated with metformin, the recommended dose of dapagliflozin is 10mg once daily. The dose of this medicine should provide the patient's current metformin dose or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. For patients switching to this medicine from combination therapy with dapagliflozin and metformin, treatment with this medicine may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to decline in elderly patients, this medicine should be used with caution as age increases.

Precautions

This medication is used for the treatment of diabetes and contains metformin and dapagliflozin. This medication should not be administered to patients with impaired renal function or liver issues, and caution is also needed in cases of acute infections, dehydration, or cardiac problems. During the course of this medication, a rare but serious side effect known as lactic acidosis may occur; therefore, if symptoms such as fatigue, muscle pain, or difficulty breathing appear, consult a doctor immediately. Moreover, this medication may cause hypoglycemia, so when used with insulin or other hypoglycemic agents, blood sugar changes should be carefully monitored, and dosage adjustment may be necessary. This medication may cause decreased fluid volume and low blood pressure; hence, especially elderly patients or those on diuretics should frequently check their blood pressure and fluid status. The risk of genital infections and urinary tract infections may increase, so if symptoms of infection appear, prompt treatment should be sought. Women who are pregnant or breastfeeding should not use this medication, and those planning a pregnancy or confirming pregnancy must discontinue use immediately. This drug may cause vitamin B12 deficiency, so it is advisable to monitor blood levels of vitamin B12 during prolonged use. In case of overdose, immediate medical attention is required; dizziness may occur as a side effect, so caution is advised while driving or operating machinery. Finally, this medication should be kept out of reach of children and stored in its original container to prevent quality degradation and misuse.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvitis
  • balanitis
  • genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • fluid volume depletion
  • thirst
Show 80 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • pruritus of the vulva
  • pruritus of the genitals
  • increased hematocrit
  • decreased creatinine clearance
  • dyslipidemia
  • elevated blood creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendonitis
  • chest pain
  • thermal burn
  • wrist fracture
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • paresthesia
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • herpes zoster
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood glucose
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarthritis
  • tendonitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasion
  • pruritus
  • benign prostatic hyperplasia
  • palpitations
  • insomnia
  • Type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air or moisture from entering. It is best to store at room temperature between 1°C and 30°C. Proper storage helps maintain the effectiveness of the medication for a longer duration.

Appearance and packaging

Appearance

Orange to dark orange rectangular film-coated double-layer tablet consisting of immediate-release layer and sustained-release layer

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.